Skip to main content

Egrifta Side Effects

Generic name: tesamorelin

Medically reviewed by Last updated on Oct 3, 2023.

Note: This document contains side effect information about tesamorelin. Some dosage forms listed on this page may not apply to the brand name Egrifta.

Applies to tesamorelin: subcutaneous powder for solution.

Serious side effects of Egrifta

Along with its needed effects, tesamorelin (the active ingredient contained in Egrifta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tesamorelin:

More common

Less common

Other side effects of Egrifta

Some side effects of tesamorelin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to tesamorelin: subcutaneous powder for injection.


Very common (10% or more): Arthralgia (13.3%)

Common (1% to 10%): Pain in extremity, myalgia, musculoskeletal pain, musculoskeletal stiffness, joint stiffness, muscle spasms, joint swelling, muscle strain[Ref]


Common (1% to 10%): Injection site erythema, injection site pruritus, injection site pain, injection site irritation, injection site hemorrhage, injection site urticaria, injection site swelling, injection site reaction, injection site rash[Ref]

Nervous system

Common (1% to 10%): Paresthesia, hypoesthesia, carpal tunnel syndrome, peripheral neuropathy[Ref]


Common (1% to 10%): Nausea, vomiting, dyspepsia, abdominal pain upper[Ref]


Common (1% to 10%): Diabetes

Uncommon (0.1% to 1%): Increased HbA1c[Ref]


Common (1% to 10%): Palpitations, hypertension, hot flush[Ref]


Common (1% to 10%): Depression, insomnia[Ref]


Common (1% to 10%): Rash, pruritus, night sweats[Ref]


Common (1% to 10%): Peripheral edema, pain, chest pain, blood creatine phosphokinase increased


Very common (10% or more): Anti- tesamorelin (the active ingredient contained in Egrifta) IgG antibodies (49.5%)


1. Product Information. Egrifta (tesamorelin). Theratechnologies Inc. 2010.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.